Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism
Применение антагонистов минералокортикоидных рецепторов до адреналэктомии при первичном альдостеронизме
2025-10-03
SCID: 54.1/zahye27n
Discuss with AI
Mineralocorticoid Receptor Antagonist (MRA)Primary Aldosteronism (PA)postoperative hyperkalemia riskpre-adrenalectomypreoperative MRA therapy
Figures from the paper
Abstract (AI)
CONTEXT: Perioperative use of mineralocorticoid receptor antagonists (MRA) in patients with unilateral primary aldosteronism (PA) awaiting surgery is not well standardized. OBJECTIVE: The aim of this study was to compare the risk of postoperative complications and surgical outcomes between PA patients treated with MRA prior to adrenalectomy and those not pretreated. METHODS: Adrenalectomized patients for unilateral PA from the SPAIN-ALDO registry, with clinical, hormonal, and treatment information before and after adrenalectomy, were analyzed. RESULTS: A total of 355 surgically treated patients were included; 76.9% (n = 273) received presurgical treatment with MRA (spironolactone [64.5%], eplerenone [35.5%]). Adrenalectomy was guided by lateralization at adrenal venous sampling in 33.5% of the overall cohort, and by imaging in all the other cases. Patients pretreated with MRA had longer duration of hypertension, higher prevalence of hypokalemia, and greater aldosterone concentrations than those not pretreated (n = 82). No differences in the rate of postsurgical hyperkalemia, hypoaldosteronism, renal function impairment, blood pressure changes, and biochemical outcomes were detected between groups in the immediate (≤30 days) and short-term (≤90 days) follow-up evaluations after surgery. At long-term follow-up (≥6 months), patients pretreated with MRA exhibited better postsurgical biochemical outcomes (81.7% had complete biochemical response vs 57.1% of non-pretreated patients; P = .004). In the multivariable analysis, the use of MRA prior to adrenalectomy was independently associated with a successful postsurgical biochemical response. CONCLUSION: Preoperative MRA therapy can be safely introduced to control blood pressure and potassium levels in patients with PA awaiting surgery, without increasing the risk of postoperative hyperkalemia, hypoaldosteronism, renal impairment, or hypotension.
Key Findings
1
Preoperative MRA therapy does not increase the risk of postoperative hyperkalemia in PA patients.
2
Preoperative MRA therapy does not increase the risk of postoperative hypoaldosteronism in PA patients.
3
Preoperative MRA therapy does not increase the risk of postoperative hypotension in PA patients.
4
Preoperative MRA therapy does not increase the risk of postoperative renal impairment in PA patients.
5
Preoperative MRA therapy safely controls potassium levels in PA patients awaiting adrenalectomy.
6
Preoperative mineralocorticoid receptor antagonist (MRA) therapy safely controls blood pressure in primary aldosteronism (PA) patients awaiting adrenalectomy.
Research Object
Preoperative mineralocorticoid receptor antagonist (MRA) therapy in patients with primary aldosteronism awaiting adrenalectomy
Research Subject
Safety and effectiveness of pre-adrenalectomy MRA therapy for controlling blood pressure and potassium levels and its impact on postoperative risks (hyperkalemia, hypoaldosteronism), renal function, and hypotension
Publication Details
Publication Date
2025-10-03
Journal
Publisher
ISSN
Cited by
8
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging2015
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023